Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · WOCKPHARMA

WOCKHARDT

HealthcarePharmaceuticals & Biotechnology₹32939 cr market cap
₹2187.00 ▲ +7.91% today As of 19 Nov 2026
52-week low ₹1100.3052-week high ₹2329.70

-13.0% from the 52-week high · +84.2% above the low

Wockhardt Ltd. engages in the pharmaceutical business. The company is headquartered in Mumbai, Maharashtra and currently employs 2,962 full-time employees. The firm's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. The company manufactures a range of dosage forms, including sterile injectables and lyophilized products. The firm offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The firm has approximately three research centers globally and a chain of six super-specialty hospitals across Maharashtra and Gujarat.

The short version. WOCKHARDT reported revenue of ₹969 crore for Sep 2026, up 23.9% from a year earlier. Net profit was ₹79 crore (up 1.3% year on year). Return on equity was 4.3% in Mar 2026. Promoter holding was 49.32% in Sep 2026, up 0.23 points over 8 quarters.

1 · The price

How has the stock traded?

WOCKHARDT trades 13.0% below its 52-week high and 84.2% above its 52-week low.

Change over period: —

1M+6.3%
3M+11.0%
6M+25.7%
1Y+50.7%

2 · The business

Is it growing?

Sales, year on year+23.9%

Sep 2026 revenue of ₹969 cr.

Profit, year on year+1.3%

Sep 2026 net profit of ₹79 cr.

Net margin8.2%

1.8 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue969929965888782738743721
Net profit791061665978-90-2514
Net margin %8.211.417.26.610.0-12.2-3.41.9
EPS (₹)4.866.5210.223.634.8-5.54-1.540.86

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue33733012279826513230270828444158
Net profit213-47-463-559-244686-69-195
Net margin %6.3-1.6-16.5-21.1-7.625.3-2.4-4.7
EPS (₹)13.11-2.89-30.18-38.8-16.9447.64-4.81-13.52

3 · The quality

How well does it turn capital into profit?

Return on equity was 4.3% in Mar 2026; debt to equity is 0.43.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %4.3-1.1-13.8-16.7
Return on capital %6.53.9-2.4-7.6
EBITDA margin %19.514.83.8-2.6
Net margin %6.1-1.5-16.1-20.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR7.9%4.2%
Profit CAGR—-20.9%
Debt to equity0.43
Interest cover2.1x
Current ratio1.61
P/E ratio80.8

4 · The owners

Who holds it, and are they adding?

Promoter holding49.32%

Up 0.23 pts over 8 quarters.

Foreign institutions7.02%

Up 0.48 pts over 8 quarters.

Domestic institutions9.0%

Down 0.82 pts over 8 quarters.

Mutual fund schemes91

+25 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter49.0949.0949.0949.0849.0849.0849.0849.32+0.23
FII6.546.817.297.16.997.097.227.02+0.48
DII9.8210.5911.0111.0110.5510.969.249.0-0.82
Public34.5333.532.632.7933.3532.8334.4434.64+0.11

Mutual fund holdings · Oct 2026

91 schemes hold this stock

66 the month before.

  • ITI Focused Fund4.42% of NAV
  • TATA SMALL CAP FUND3.38% of NAV
  • TATA LARGE & MID CAP FUND2.7% of NAV
  • ITI Balanced Advantage Fund2.41% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND2.37% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund2.36% of NAV
  • HSBC India Export Opportunities Fund2.35% of NAV
  • Kotak Nifty Smallcap 50 Index Fund1.9% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for WOCKHARDT are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about WOCKHARDT

What is the WOCKHARDT share price?

WOCKHARDT (WOCKPHARMA) last closed at ₹2,187.00, up 7.91% on the day. Its 52-week range is ₹1,100.30 to ₹2,329.70.

What is the market cap of WOCKHARDT?

WOCKHARDT has a market capitalisation of about ₹32,939 crore. Its price-to-earnings ratio is 80.8.

How are WOCKHARDT's latest results?

WOCKHARDT reported revenue of ₹969 crore for Sep 2026, up 23.9% from a year earlier. Net profit was ₹79 crore (up 1.3% year on year). Return on equity was 4.3% in Mar 2026. Promoter holding was 49.32% in Sep 2026, up 0.23 points over 8 quarters.

Who owns WOCKHARDT?

As of Sep 2026, shareholding was: Promoter 49.32%, FII 7.02%, DII 9.0%, Public 34.64%.

How many mutual funds hold WOCKHARDT?

91 mutual fund schemes held WOCKHARDT in October 2026. That compares with 66 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 08 Mar 2022 · Rights issue 3:10
  • 17 Nov 2016 · Interim Dividend - Rs. 10
  • 13 Nov 2014 · Interim Dividend - Rs. 20
  • 17 Feb 2014 · Interim Dividend - Rs. 5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.